scholarly journals Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema

2005 ◽  
Vol 89 (1) ◽  
pp. 122-122 ◽  
Author(s):  
J B Jonas
Keyword(s):  
Intravitreal Injection ◽  
Triamcinolone Acetonide ◽  
Macular Oedema ◽  
Diabetic Macular Oedema

scholarly journals Efficacy and Safety of Intravitreal Injection Ranibizumab versus Triamcinolone Acetonide in Diabetic Macular Oedema - A Prospective Randomized Study, Gorakhpur, Uttar Pradesh

2021 ◽  
Vol 8 (27) ◽  
pp. 2444-2450
Author(s):  
Ramyash Singh Yadav ◽  
Ram Kumar Jaiswal ◽  
Punita Tripathi ◽  
Mridula Ranjan ◽  
Chiranji Rai
Keyword(s):  
Visual Acuity ◽  
Intravitreal Injection ◽  
Triamcinolone Acetonide ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Foveal Thickness ◽  
Corrected Visual Acuity ◽  
Group A ◽  
Group B ◽  
Best Corrected Visual Acuity

BACKGROUND Diabetic macular oedema is a sight threatening complication of diabetic retinopathy. Vascular endothelial growth factor (VEGF) plays an important role in developing diabetic macular oedema. There are many treatment options available for diabetic macular oedema such as laser therapy, intravitreal injectable medications like anti-VEGF and steroids. This study intends to compare the efficacy and safety of intravitreal injection Ranibizumab (anti-VEGF) and Triamcinolone acetonide (steroid) in diabetic macular oedema. METHODS This is a prospective randomized study conducted among 42 patients ≥ 18 years of age with diabetic macular oedema presenting to outpatient department in a tertiary care centre in Gorakhpur, UP, conducted from November 2019 – December 2020. 42 participating patients were divided into 2 groups, A and B with 21 patients in each group. Group A treated with intravitreal injection Ranibizumab (0.05 ml ; 0.50 mg) and group B treated with intravitreal injection Triamcinolone acetonide (4 mg in 0.1 ml). All patients were followed-up at 2 week and 4 week after injection for best corrected visual acuity, intraocular pressure, foveal and para-foveal thickness. Optical coherence tomography was performed for measuring foveal and para-foveal thickness. RESULTS The mean age group being 56.48 years in group A and 58.63 years in group B with 12 male and 9 female patients in group A and 10 male and 11 female patients in group B with no dropout during study period. Both injections were equally effective in reducing foveal and para-foveal thickness and improving best corrected visual acuity. Intraocular pressure (IOP) was stable in Ranibizumab treated group but Triamcinolone treated group showed raised IOP in few patients, required anti-glaucoma medications. CONCLUSIONS Both treatment types had good efficacy in reducing foveal and para-foveal thickness and thus improving best corrected visual acuity, but intravitreal Ranibizumab is safer and well tolerated along with good efficacy in patients with diabetic macular oedema. KEYWORDS Best Corrected Visual Acuity, Diabetic Macular Oedema, Foveal and Para-Foveal Thickness, Intravitreal Ranibizumab, Intravitreal Triamcinolone Acetonide

Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema

2011 ◽  
Vol 90 (2) ◽  
pp. e160-e161 ◽  
Author(s):  
Fernando Marcondes Penha ◽  
Mauricio Maia ◽  
José Augusto Cardillo ◽  
J. Fernando Arevalo ◽  
Lihteh Wu ◽  
...  
Keyword(s):  
Intravitreal Injection ◽  
Triamcinolone Acetonide ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Primary Treatment

scholarly journals Single intravitreal injection of triamcinolone combined with bevacizumab for the treatment of diffuse diabetic macular oedema refractory to grid photocoagulation

2009 ◽  
Vol 88 (7) ◽  
pp. e297-e298 ◽  
Author(s):  
Marco S. Folgosa ◽  
André Messias ◽  
Clécio Takata ◽  
Rogério A. Costa ◽  
Ingrid U. Scott ◽  
...  
Keyword(s):  
Intravitreal Injection ◽  
Macular Oedema ◽  
Diabetic Macular Oedema

scholarly journals Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema

2008 ◽  
Vol 86 (7) ◽  
pp. 800-805 ◽  
Author(s):  
Xiaoyun Fang ◽  
Hirokazu Sakaguchi ◽  
Fumi Gomi ◽  
Yusuke Oshima ◽  
Miki Sawa ◽  
...  
Keyword(s):  
Intravitreal Injection ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Efficacy And Safety

scholarly journals Effect of intravitreal Triamcinolone (2mg) on diabetic macular oedema in the pseudophakic patient as primary treatment

2020 ◽  
Vol 11 (3) ◽  
pp. 3533-3539
Author(s):  
Mohammed Qasim Al Nuwaini ◽  
Giyathaldeen T. Neameh ◽  
Mustafa A. Al Zubaidi Md ◽  
Farook M. Albusultan
Keyword(s):  
Visual Acuity ◽  
Intraocular Pressure ◽  
Intravitreal Injection ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Visual Outcome ◽  
Primary Treatment ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Intravitreal Triamcinolone

Diabetic macular oedema is still a significant cause of vision drop in the diabetic patient with no definitive regime for treatment. This study was on the result of effects of intravitreal injection of (2mg) triamcinolone on central macular thickness measured by OCT, visual acuity and intraocular pressure in pseudophakic eyes with diabetic macular oedema as a primary treatment line followed in six months. This study is a prospective, interventional case study series. It was on patients who received intravitreal injection of Triamcinolone in a single dose of ( 2 mg/0. 05 ml). Central macular thickness by OCT, visual acuity, and intraocular pressure was measured pre-injection and 1,3,6 months after injection. This study was performed in Iraq, Baghdad, Ibn Al-Haitham Teaching Eye Hospital from October 2014 to July 2015. Results showed 25 eyes received intravitreal injection of Triamcinolone Acetoniod with pre-injection central macular thickness 597.9+98.02 µm, visual acuity 1.096+0.61 Log MAR and intraocular pressure of 16.5+ 2.53 mmHg. After six months of follow up on central macular thickness 341.6+163.1 µm, visual acuity was 0.63 + 0.40 Log MAR and IOP was 18. 04+ 5. 63mmHg. This study suggests that intravitreal injection of Triamcinolone in a dose 2mg / 0. 05ml improves both anatomical and visual outcome in 21 eyes (84%) out of 25 pseudophakic eyes with diabetic macular oedema during first six months after injection and an increase in intraocular pressure in 2 eyes (8%). The intraocular pressure was despite the use of anti-glaucoma medications during this period.

scholarly journals Can Needle Bevel Tip Orientation Influence Pain Perception Associated with Intravitreal Injection?

2021 ◽  
Author(s):  
Rakesh Kumar Jha ◽  
Sankalp Seth
Keyword(s):  
Intravitreal Injection ◽  
Macular Oedema ◽  
Pain Perception ◽  
Tertiary Care ◽  
Diabetic Macular Oedema ◽  
Age Related Macular Degeneration ◽  
Tertiary Care Centre ◽  
Chi Square ◽  
Age Related ◽  
Oriented Parallel

Introduction: Reduction of pain perception associated with intravitreal injections is crucial factor for improving compliance of the patient to the planned subsequent injections. Aim: This study aimed to evaluate relation of pain perception with initial needle bevel tip orientation during intravitreal injection. Materials and Methods: A prospective interventional study conducted on 120 eyes of 120 patients at the single tertiary care centre between December 2017 to January 2020 , who never underwent any intravitreal injection and were planned for their first intravitreal injection of ranibizumab in either of their clinically indicated eye for conditions such as Neo-vascular Age Related Macular Degeneration (ARMD), central Diabetic Macular Oedema (DME) and macular oedema secondary to Retinal Vein Occlusion (RVO). Fifty per cent (50%) of the patients received intravitreal injection with needle bevel tip oriented parallel to limbus margin and fifty per cent (50%) of patient received intravitreal injection with needle bevel tip oriented perpendicular to the limbus margin. The primary outcome was to compare the level of pain perception of the subject patients by using Visual Analogue Scale (VAS) in the immediate postprocedure period. Data collected in MS excel and analysed by using SPSS Version 24.0. Independent t-test was used for the comparison of the two groups. Chi-square test was used for the comparison of nominal variables of subject groups. Pearson’s correlation test was used to evaluate the relationship between quantitative variables and pain scores. The p-values smaller than (<0.05) were considered as statistically significant. Results: Pain perception scores assessed on the VAS (0-100mm) ranged from 0.8 to 39, with a mean of 18.13±7.65. Significant correlation was found with two different mode of orientation of needle bevel tip. Patients perceived less pain with needle bevel tip oriented perpendicular to the limbus margin compared to parallel to limbus margin (p=0.0001). Conclusion: Pain perception associated with intravitreal injection can be further minimised by orientating the bevel needle tip as perpendicular to limbus margin while initiating the insertion of injection into the indicated eye.

scholarly journals Triamcinolone Acetonide for the Treatment of Diabetic Macular Oedema

2010 ◽  
Vol 8 (1) ◽  
pp. 42
Author(s):  
Valentina Sarao ◽  
Daniele Veritti ◽  
Paolo Lanzetta ◽  
◽  
◽  
...  
Keyword(s):  
Triamcinolone Acetonide ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Standard Of Care ◽  
Blood Retinal Barrier ◽  
Intravitreal Triamcinolone ◽  
Duration Of Action ◽  
Routes Of Administration ◽  
Severe Visual Loss ◽  
Randomised Controlled

Diabetic macular oedema is a major cause of severe visual loss whose pathogenesis appears to be complex and multifactorial. For many years laser photocoagulation has been the standard of care for the treatment of this condition. Emerging pharmacologic approaches are being evaluated through randomised controlled trials. Triamcinolone acetonide has been proposed as a promising option, due to its well-known anti-inflammatory, anti-permeability and anti-angiogenic properties. Intravitreal delivery allows bypassing of the blood–retinal barrier to achieve a more concentrated dose of steroid in the vitreal cavity for a prolonged time. Intravitreal triamcinolone acetonide is effective in reducing central macular thickness and improving visual acuity, even if the duration of action is often provisional and requires repeated injections. Drug-related and injection-related side effects have been reported; the most common are induced cataract and increased intraocular pressure. To extend the duration of steroid effects and to minimise the risk of complications, alternative routes of administration and extend-release implants are being investigated.

Sign in / Sign up

Export Citation Format

Share Document